PMID- 38351500
OWN - NLM
STAT- Publisher
LR  - 20240214
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
DP  - 2024 Feb 14
TI  - Comparative Levels of Urinary Biomarkers of Renal Injury and Inflammation Among 
      Patients With Diabetic Nephropathy With or Without Hyperuricemia.
LID - 10.1097/RHU.0000000000002068 [doi]
AB  - BACKGROUND: The association between hyperuricemia and development of progressive 
      chronic kidney disease has received increasing attention in recent years. Recent 
      preclinical studies have shown that non-crystalline uric acid can induce 
      renal-specific arteriolopathy, leading to renal injury and tubulointerstitial 
      inflammation. METHODS: We conducted a open-label cross-sectional study of 25 
      patients with chronic kidney disease stage III (estimated glomerular filtration 
      rate [eGFR], 7.0 mg/dL) levels of serum uric acid. To determine the correlation 
      between hyperuricemia on urinary protein levels and renal disease progression, we 
      retrospectively compared urine protein and eGFR data between the 2 groups. 
      RESULTS: Eleven patients with normal uric acid levels and 14 with hyperuricemia 
      were enrolled. Urinary levels of both kidney injury molecule-1 (KIM-1) and 
      monocyte chemoattractant protein-1 (MCP-1) were significantly higher in patients 
      with hyperuricemia. Among the normouricemic White and African American (AA) 
      subgroups, there was no difference in KIM-1 or MCP-1 levels, whereas KIM-1 levels 
      were significantly higher among hyperuricemic AA patients with hyperuricemia. 
      Urinary protein was significantly higher between Whites and AA patients with 
      serum uric acid level >7.0 mg/dL as well as patients with urinary KIM-1 levels 
      >1000 pg/mg Cr. A trend toward a more rapid decline in eGFR was noted among 
      hyperuricemic AAs; however, this trend was not statistically significant. 
      CONCLUSIONS: Patients with type 2 diabetic nephropathy and persistently elevated 
      serum uric acid levels express higher levels of both KIM-1 and MCP-1 reflective 
      of on-going renal injury and inflammation.
CI  - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Alex, Ryan
AU  - Alex R
AD  - From the NephroNet Clinical Trials Consortium, Atlanta, GA.
FAU - Press, Ella
AU  - Press E
AD  - From the NephroNet Clinical Trials Consortium, Atlanta, GA.
FAU - Sanchez, Lorin
AU  - Sanchez L
AD  - From the NephroNet Clinical Trials Consortium, Atlanta, GA.
FAU - Whitson, Jeremy
AU  - Whitson J
AD  - From the NephroNet Clinical Trials Consortium, Atlanta, GA.
FAU - Marder, Brad
AU  - Marder B
AD  - Horizon Therapeutics, Deerfield, IL.
FAU - Tumlin, James Alan
AU  - Tumlin JA
LA  - eng
PT  - Journal Article
DEP - 20240214
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
SB  - IM
COIS- The authors declare no conflict of interest.
EDAT- 2024/02/14 06:43
MHDA- 2024/02/14 06:43
CRDT- 2024/02/14 00:07
PHST- 2024/02/14 06:43 [medline]
PHST- 2024/02/14 06:43 [pubmed]
PHST- 2024/02/14 00:07 [entrez]
AID - 00124743-990000000-00188 [pii]
AID - 10.1097/RHU.0000000000002068 [doi]
PST - aheadofprint
SO  - J Clin Rheumatol. 2024 Feb 14. doi: 10.1097/RHU.0000000000002068.